Medicus Pharma (NASDAQ:MDCX) said on Monday that new analysis of data from a mid-stage clinical trial of its SkinJect ...

A clinical trial found nicotinamide, a form of vitamin B3, may help reduce skin cancer risk. Participants who took ...

Oncopatch represents a meaningful addition to the treatment landscape for skin cancer…particularly in situations where ...

CEO Dr. Raza Bokhari talked with Proactive about the company’s newly reported topline Phase 2 results for its microneedle ...

A BBC star has tragically revealed he is battling terminal cancer and “entering the last stages”. The actor, who stars on ...

Heaven’s Beverley Mitchell reflected on a life-changing experience when doctors found the “biggest precancerous polyp” on her ...

The South Jersey biotech also secured a $22 million ARPA-H grant and additional investment to advance its research on therapies targeting aging.

Amid Teddi Mellencamp’s ongoing battle with stage 4 melanoma, she shared she was recently hospitalized for contracting Stevens-Johnson’s syndrome, a rare, life-threatening illness.

Increasing use of Mohs micrographic surgery was observed from 2011 to 2022, with no significant differences seen in patients of varying skin colors.

In this study, researchers aimed to fill gaps in the knowledge of treatment management and outcomes in melanoma patients aged 75 years and older.

Medicus Pharma Ltd. MDCX shares surged to a high of $1.61 before falling during Thursday’s premarket session following the ...

YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40 ...